The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Anti-VEGF Medicine Market Research Report 2025
Synopsis
The global Anti-VEGF Medicine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Anti-VEGF Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-VEGF Medicine.
Report Scope
The Anti-VEGF Medicine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-VEGF Medicine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-VEGF Medicine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Faricimab
Bayer (Regeneron)
Brolucizumab
Kanghong Pharmaceutical
Santen
Segment by Type
Single Target (Ranibizumab, etc.)
Multiple Targets (Aflibercept, Conbercept, etc.)
Segment by Application
Hospital
Eye Clinic
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anti-VEGF Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anti-VEGF Medicine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Anti-VEGF Medicine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Anti-VEGF Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-VEGF Medicine.
Report Scope
The Anti-VEGF Medicine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-VEGF Medicine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-VEGF Medicine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Faricimab
Bayer (Regeneron)
Brolucizumab
Kanghong Pharmaceutical
Santen
Segment by Type
Single Target (Ranibizumab, etc.)
Multiple Targets (Aflibercept, Conbercept, etc.)
Segment by Application
Hospital
Eye Clinic
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anti-VEGF Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anti-VEGF Medicine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Anti-VEGF Medicine Market Overview
1.1 Product Overview and Scope of Anti-VEGF Medicine
1.2 Anti-VEGF Medicine Segment by Type
1.2.1 Global Anti-VEGF Medicine Market Value Comparison by Type (2024-2030)
1.2.2 Single Target (Ranibizumab, etc.)
1.2.3 Multiple Targets (Aflibercept, Conbercept, etc.)
1.3 Anti-VEGF Medicine Segment by Application
1.3.1 Global Anti-VEGF Medicine Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Eye Clinic
1.3.4 Other
1.4 Global Anti-VEGF Medicine Market Size Estimates and Forecasts
1.4.1 Global Anti-VEGF Medicine Revenue 2019-2030
1.4.2 Global Anti-VEGF Medicine Sales 2019-2030
1.4.3 Global Anti-VEGF Medicine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Anti-VEGF Medicine Market Competition by Manufacturers
2.1 Global Anti-VEGF Medicine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Anti-VEGF Medicine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Anti-VEGF Medicine Average Price by Manufacturers (2019-2024)
2.4 Global Anti-VEGF Medicine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Anti-VEGF Medicine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Anti-VEGF Medicine, Product Type & Application
2.7 Anti-VEGF Medicine Market Competitive Situation and Trends
2.7.1 Anti-VEGF Medicine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Anti-VEGF Medicine Players Market Share by Revenue
2.7.3 Global Anti-VEGF Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Anti-VEGF Medicine Retrospective Market Scenario by Region
3.1 Global Anti-VEGF Medicine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Anti-VEGF Medicine Global Anti-VEGF Medicine Sales by Region: 2019-2030
3.2.1 Global Anti-VEGF Medicine Sales by Region: 2019-2024
3.2.2 Global Anti-VEGF Medicine Sales by Region: 2025-2030
3.3 Global Anti-VEGF Medicine Global Anti-VEGF Medicine Revenue by Region: 2019-2030
3.3.1 Global Anti-VEGF Medicine Revenue by Region: 2019-2024
3.3.2 Global Anti-VEGF Medicine Revenue by Region: 2025-2030
3.4 North America Anti-VEGF Medicine Market Facts & Figures by Country
3.4.1 North America Anti-VEGF Medicine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Anti-VEGF Medicine Sales by Country (2019-2030)
3.4.3 North America Anti-VEGF Medicine Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Anti-VEGF Medicine Market Facts & Figures by Country
3.5.1 Europe Anti-VEGF Medicine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Anti-VEGF Medicine Sales by Country (2019-2030)
3.5.3 Europe Anti-VEGF Medicine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anti-VEGF Medicine Market Facts & Figures by Country
3.6.1 Asia Pacific Anti-VEGF Medicine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Anti-VEGF Medicine Sales by Country (2019-2030)
3.6.3 Asia Pacific Anti-VEGF Medicine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Anti-VEGF Medicine Market Facts & Figures by Country
3.7.1 Latin America Anti-VEGF Medicine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Anti-VEGF Medicine Sales by Country (2019-2030)
3.7.3 Latin America Anti-VEGF Medicine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Anti-VEGF Medicine Market Facts & Figures by Country
3.8.1 Middle East and Africa Anti-VEGF Medicine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Anti-VEGF Medicine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Anti-VEGF Medicine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Anti-VEGF Medicine Sales by Type (2019-2030)
4.1.1 Global Anti-VEGF Medicine Sales by Type (2019-2024)
4.1.2 Global Anti-VEGF Medicine Sales by Type (2025-2030)
4.1.3 Global Anti-VEGF Medicine Sales Market Share by Type (2019-2030)
4.2 Global Anti-VEGF Medicine Revenue by Type (2019-2030)
4.2.1 Global Anti-VEGF Medicine Revenue by Type (2019-2024)
4.2.2 Global Anti-VEGF Medicine Revenue by Type (2025-2030)
4.2.3 Global Anti-VEGF Medicine Revenue Market Share by Type (2019-2030)
4.3 Global Anti-VEGF Medicine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Anti-VEGF Medicine Sales by Application (2019-2030)
5.1.1 Global Anti-VEGF Medicine Sales by Application (2019-2024)
5.1.2 Global Anti-VEGF Medicine Sales by Application (2025-2030)
5.1.3 Global Anti-VEGF Medicine Sales Market Share by Application (2019-2030)
5.2 Global Anti-VEGF Medicine Revenue by Application (2019-2030)
5.2.1 Global Anti-VEGF Medicine Revenue by Application (2019-2024)
5.2.2 Global Anti-VEGF Medicine Revenue by Application (2025-2030)
5.2.3 Global Anti-VEGF Medicine Revenue Market Share by Application (2019-2030)
5.3 Global Anti-VEGF Medicine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Faricimab
6.1.1 Faricimab Corporation Information
6.1.2 Faricimab Description and Business Overview
6.1.3 Faricimab Anti-VEGF Medicine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Faricimab Anti-VEGF Medicine Product Portfolio
6.1.5 Faricimab Recent Developments/Updates
6.2 Bayer (Regeneron)
6.2.1 Bayer (Regeneron) Corporation Information
6.2.2 Bayer (Regeneron) Description and Business Overview
6.2.3 Bayer (Regeneron) Anti-VEGF Medicine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Bayer (Regeneron) Anti-VEGF Medicine Product Portfolio
6.2.5 Bayer (Regeneron) Recent Developments/Updates
6.3 Brolucizumab
6.3.1 Brolucizumab Corporation Information
6.3.2 Brolucizumab Description and Business Overview
6.3.3 Brolucizumab Anti-VEGF Medicine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Brolucizumab Anti-VEGF Medicine Product Portfolio
6.3.5 Brolucizumab Recent Developments/Updates
6.4 Kanghong Pharmaceutical
6.4.1 Kanghong Pharmaceutical Corporation Information
6.4.2 Kanghong Pharmaceutical Description and Business Overview
6.4.3 Kanghong Pharmaceutical Anti-VEGF Medicine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Kanghong Pharmaceutical Anti-VEGF Medicine Product Portfolio
6.4.5 Kanghong Pharmaceutical Recent Developments/Updates
6.5 Santen
6.5.1 Santen Corporation Information
6.5.2 Santen Description and Business Overview
6.5.3 Santen Anti-VEGF Medicine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Santen Anti-VEGF Medicine Product Portfolio
6.5.5 Santen Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-VEGF Medicine Industry Chain Analysis
7.2 Anti-VEGF Medicine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-VEGF Medicine Production Mode & Process
7.4 Anti-VEGF Medicine Sales and Marketing
7.4.1 Anti-VEGF Medicine Sales Channels
7.4.2 Anti-VEGF Medicine Distributors
7.5 Anti-VEGF Medicine Customers
8 Anti-VEGF Medicine Market Dynamics
8.1 Anti-VEGF Medicine Industry Trends
8.2 Anti-VEGF Medicine Market Drivers
8.3 Anti-VEGF Medicine Market Challenges
8.4 Anti-VEGF Medicine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Anti-VEGF Medicine Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Anti-VEGF Medicine Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Anti-VEGF Medicine Market Competitive Situation by Manufacturers in 2023
Table 4. Global Anti-VEGF Medicine Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Anti-VEGF Medicine Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Anti-VEGF Medicine Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Anti-VEGF Medicine Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Anti-VEGF Medicine Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Anti-VEGF Medicine, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Anti-VEGF Medicine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Anti-VEGF Medicine, Product Type & Application
Table 12. Global Key Manufacturers of Anti-VEGF Medicine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Anti-VEGF Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGF Medicine as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Anti-VEGF Medicine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Anti-VEGF Medicine Sales by Region (2019-2024) & (K Units)
Table 18. Global Anti-VEGF Medicine Sales Market Share by Region (2019-2024)
Table 19. Global Anti-VEGF Medicine Sales by Region (2025-2030) & (K Units)
Table 20. Global Anti-VEGF Medicine Sales Market Share by Region (2025-2030)
Table 21. Global Anti-VEGF Medicine Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Anti-VEGF Medicine Revenue Market Share by Region (2019-2024)
Table 23. Global Anti-VEGF Medicine Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Anti-VEGF Medicine Revenue Market Share by Region (2025-2030)
Table 25. North America Anti-VEGF Medicine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Anti-VEGF Medicine Sales by Country (2019-2024) & (K Units)
Table 27. North America Anti-VEGF Medicine Sales by Country (2025-2030) & (K Units)
Table 28. North America Anti-VEGF Medicine Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Anti-VEGF Medicine Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Anti-VEGF Medicine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Anti-VEGF Medicine Sales by Country (2019-2024) & (K Units)
Table 32. Europe Anti-VEGF Medicine Sales by Country (2025-2030) & (K Units)
Table 33. Europe Anti-VEGF Medicine Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Anti-VEGF Medicine Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Anti-VEGF Medicine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Anti-VEGF Medicine Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Anti-VEGF Medicine Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Anti-VEGF Medicine Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Anti-VEGF Medicine Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Anti-VEGF Medicine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Anti-VEGF Medicine Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Anti-VEGF Medicine Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Anti-VEGF Medicine Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Anti-VEGF Medicine Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Anti-VEGF Medicine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Anti-VEGF Medicine Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Anti-VEGF Medicine Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Anti-VEGF Medicine Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Anti-VEGF Medicine Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Anti-VEGF Medicine Sales (K Units) by Type (2019-2024)
Table 51. Global Anti-VEGF Medicine Sales (K Units) by Type (2025-2030)
Table 52. Global Anti-VEGF Medicine Sales Market Share by Type (2019-2024)
Table 53. Global Anti-VEGF Medicine Sales Market Share by Type (2025-2030)
Table 54. Global Anti-VEGF Medicine Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Anti-VEGF Medicine Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Anti-VEGF Medicine Revenue Market Share by Type (2019-2024)
Table 57. Global Anti-VEGF Medicine Revenue Market Share by Type (2025-2030)
Table 58. Global Anti-VEGF Medicine Price (US$/Unit) by Type (2019-2024)
Table 59. Global Anti-VEGF Medicine Price (US$/Unit) by Type (2025-2030)
Table 60. Global Anti-VEGF Medicine Sales (K Units) by Application (2019-2024)
Table 61. Global Anti-VEGF Medicine Sales (K Units) by Application (2025-2030)
Table 62. Global Anti-VEGF Medicine Sales Market Share by Application (2019-2024)
Table 63. Global Anti-VEGF Medicine Sales Market Share by Application (2025-2030)
Table 64. Global Anti-VEGF Medicine Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Anti-VEGF Medicine Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Anti-VEGF Medicine Revenue Market Share by Application (2019-2024)
Table 67. Global Anti-VEGF Medicine Revenue Market Share by Application (2025-2030)
Table 68. Global Anti-VEGF Medicine Price (US$/Unit) by Application (2019-2024)
Table 69. Global Anti-VEGF Medicine Price (US$/Unit) by Application (2025-2030)
Table 70. Faricimab Corporation Information
Table 71. Faricimab Description and Business Overview
Table 72. Faricimab Anti-VEGF Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Faricimab Anti-VEGF Medicine Product
Table 74. Faricimab Recent Developments/Updates
Table 75. Bayer (Regeneron) Corporation Information
Table 76. Bayer (Regeneron) Description and Business Overview
Table 77. Bayer (Regeneron) Anti-VEGF Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Bayer (Regeneron) Anti-VEGF Medicine Product
Table 79. Bayer (Regeneron) Recent Developments/Updates
Table 80. Brolucizumab Corporation Information
Table 81. Brolucizumab Description and Business Overview
Table 82. Brolucizumab Anti-VEGF Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Brolucizumab Anti-VEGF Medicine Product
Table 84. Brolucizumab Recent Developments/Updates
Table 85. Kanghong Pharmaceutical Corporation Information
Table 86. Kanghong Pharmaceutical Description and Business Overview
Table 87. Kanghong Pharmaceutical Anti-VEGF Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Kanghong Pharmaceutical Anti-VEGF Medicine Product
Table 89. Kanghong Pharmaceutical Recent Developments/Updates
Table 90. Santen Corporation Information
Table 91. Santen Description and Business Overview
Table 92. Santen Anti-VEGF Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Santen Anti-VEGF Medicine Product
Table 94. Santen Recent Developments/Updates
Table 95. Key Raw Materials Lists
Table 96. Raw Materials Key Suppliers Lists
Table 97. Anti-VEGF Medicine Distributors List
Table 98. Anti-VEGF Medicine Customers List
Table 99. Anti-VEGF Medicine Market Trends
Table 100. Anti-VEGF Medicine Market Drivers
Table 101. Anti-VEGF Medicine Market Challenges
Table 102. Anti-VEGF Medicine Market Restraints
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Anti-VEGF Medicine
Figure 2. Global Anti-VEGF Medicine Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Anti-VEGF Medicine Market Share by Type in 2023 & 2030
Figure 4. Single Target (Ranibizumab, etc.) Product Picture
Figure 5. Multiple Targets (Aflibercept, Conbercept, etc.) Product Picture
Figure 6. Global Anti-VEGF Medicine Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Anti-VEGF Medicine Market Share by Application in 2023 & 2030
Figure 8. Hospital
Figure 9. Eye Clinic
Figure 10. Other
Figure 11. Global Anti-VEGF Medicine Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Anti-VEGF Medicine Market Size (2019-2030) & (US$ Million)
Figure 13. Global Anti-VEGF Medicine Sales (2019-2030) & (K Units)
Figure 14. Global Anti-VEGF Medicine Average Price (US$/Unit) & (2019-2030)
Figure 15. Anti-VEGF Medicine Report Years Considered
Figure 16. Anti-VEGF Medicine Sales Share by Manufacturers in 2023
Figure 17. Global Anti-VEGF Medicine Revenue Share by Manufacturers in 2023
Figure 18. The Global 5 and 10 Largest Anti-VEGF Medicine Players: Market Share by Revenue in 2023
Figure 19. Anti-VEGF Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 20. Global Anti-VEGF Medicine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 21. North America Anti-VEGF Medicine Sales Market Share by Country (2019-2030)
Figure 22. North America Anti-VEGF Medicine Revenue Market Share by Country (2019-2030)
Figure 23. United States Anti-VEGF Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Canada Anti-VEGF Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Europe Anti-VEGF Medicine Sales Market Share by Country (2019-2030)
Figure 26. Europe Anti-VEGF Medicine Revenue Market Share by Country (2019-2030)
Figure 27. Germany Anti-VEGF Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. France Anti-VEGF Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. U.K. Anti-VEGF Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Italy Anti-VEGF Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Russia Anti-VEGF Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Anti-VEGF Medicine Sales Market Share by Region (2019-2030)
Figure 33. Asia Pacific Anti-VEGF Medicine Revenue Market Share by Region (2019-2030)
Figure 34. China Anti-VEGF Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Japan Anti-VEGF Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. South Korea Anti-VEGF Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. India Anti-VEGF Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Australia Anti-VEGF Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. China Taiwan Anti-VEGF Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Indonesia Anti-VEGF Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Thailand Anti-VEGF Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Malaysia Anti-VEGF Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Latin America Anti-VEGF Medicine Sales Market Share by Country (2019-2030)
Figure 44. Latin America Anti-VEGF Medicine Revenue Market Share by Country (2019-2030)
Figure 45. Mexico Anti-VEGF Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Brazil Anti-VEGF Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Argentina Anti-VEGF Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Anti-VEGF Medicine Sales Market Share by Country (2019-2030)
Figure 49. Middle East & Africa Anti-VEGF Medicine Revenue Market Share by Country (2019-2030)
Figure 50. Turkey Anti-VEGF Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia Anti-VEGF Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. UAE Anti-VEGF Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Global Sales Market Share of Anti-VEGF Medicine by Type (2019-2030)
Figure 54. Global Revenue Market Share of Anti-VEGF Medicine by Type (2019-2030)
Figure 55. Global Anti-VEGF Medicine Price (US$/Unit) by Type (2019-2030)
Figure 56. Global Sales Market Share of Anti-VEGF Medicine by Application (2019-2030)
Figure 57. Global Revenue Market Share of Anti-VEGF Medicine by Application (2019-2030)
Figure 58. Global Anti-VEGF Medicine Price (US$/Unit) by Application (2019-2030)
Figure 59. Anti-VEGF Medicine Value Chain
Figure 60. Anti-VEGF Medicine Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
